The FDA issued a safety communication alerting the public about interim safety results from an ongoing clinical trial th…
Oral Medication
The Hugely Inflated Prices of Glumetza and Metformin ER
I may have been very late to the astonishing price increase of Glumetza, but I am, by coincidence, among the first to re…
FDA Revises Labels of SGLT2 Inhibitors
A U.S. FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines …
Invokana Warning: Diabetes Drug May Increase Risk of Bone Fractures
Several months ago the FDA warned that SGLT2 inhibitors like Invokana may cause diabetic ketoacidosis, a condition that …
The Novo Nordisk Pipeline: An Interview with CMO Todd Hobbs
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; a…
Do SGLT2 Inhibitors like Invokana Cause Ketoacidosis?
Only a tiny number of cases of diabetic ketoacidosis have been reported with SGLT2 inhibitor treatment, so this is unlik…
FDA Approves Glyxambi, New Type 2 Diabetes Medication
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’…
Invokana Helps My Type 1 Diabetes
I emailed my endo ahead of time to give her a heads up that I wanted to discuss going on Invokana. Unfortunately, she wa…
Using Type 2 Diabetes Medication to Treat Type 1 Diabetes
There have been a number of new developments in the treatment of type 2 diabetes, and a question often asked is whether …
FDA Issues Complete Response Letter for Type 2 Diabetes Drug Empagliflozin
The FDA has issued a complete response letter to Boehringer Ingelheim and Eli Lilly for the New Drug Application (NDA) …